New Hampshire Trust Has $5.02 Million Stock Holdings in AbbVie Inc. (NYSE:ABBV)

New Hampshire Trust raised its stake in shares of AbbVie Inc. (NYSE:ABBVFree Report) by 0.4% during the 2nd quarter, HoldingsChannel reports. The firm owned 37,289 shares of the company’s stock after purchasing an additional 143 shares during the quarter. AbbVie comprises 1.3% of New Hampshire Trust’s holdings, making the stock its 18th biggest position. New Hampshire Trust’s holdings in AbbVie were worth $5,024,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABBV. Kalos Management Inc. acquired a new position in AbbVie during the first quarter valued at approximately $26,000. Boulder Wealth Advisors LLC bought a new stake in shares of AbbVie in the fourth quarter valued at approximately $31,000. Stone House Investment Management LLC bought a new stake in shares of AbbVie in the first quarter valued at approximately $37,000. True Wealth Design LLC bought a new stake in shares of AbbVie in the fourth quarter valued at approximately $39,000. Finally, General Partner Inc. bought a new stake in shares of AbbVie in the first quarter valued at approximately $40,000. Institutional investors and hedge funds own 67.86% of the company’s stock.

AbbVie Stock Up 1.2 %

Shares of NYSE:ABBV opened at $153.93 on Tuesday. AbbVie Inc. has a 52 week low of $130.96 and a 52 week high of $168.11. The company has a debt-to-equity ratio of 4.33, a quick ratio of 0.77 and a current ratio of 0.89. The company’s fifty day moving average is $146.42 and its 200-day moving average is $147.44. The company has a market capitalization of $271.69 billion, a PE ratio of 31.67, a P/E/G ratio of 2.79 and a beta of 0.58.

AbbVie (NYSE:ABBVGet Free Report) last issued its earnings results on Thursday, July 27th. The company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.79 by $0.12. AbbVie had a net margin of 15.50% and a return on equity of 151.29%. The company had revenue of $13.87 billion for the quarter, compared to the consensus estimate of $13.52 billion. Equities research analysts predict that AbbVie Inc. will post 11.03 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 15th. Stockholders of record on Friday, October 13th will be paid a $1.48 dividend. The ex-dividend date of this dividend is Thursday, October 12th. This represents a $5.92 annualized dividend and a dividend yield of 3.85%. AbbVie’s dividend payout ratio is presently 121.81%.

Insider Activity

In other news, CEO Richard A. Gonzalez sold 18,500 shares of the business’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $149.15, for a total value of $2,759,275.00. Following the sale, the chief executive officer now owns 625,294 shares in the company, valued at approximately $93,262,600.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research reports. HSBC initiated coverage on AbbVie in a research report on Friday, July 14th. They issued a “buy” rating and a $167.00 price objective for the company. Piper Sandler increased their price objective on AbbVie from $163.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, July 28th. TheStreet raised AbbVie from a “c+” rating to a “b” rating in a research report on Monday, August 28th. Piper Jaffray Companies increased their price objective on AbbVie from $163.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, July 28th. Finally, StockNews.com assumed coverage on AbbVie in a research report on Thursday, August 17th. They issued a “strong-buy” rating for the company. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $165.79.

View Our Latest Report on ABBV

About AbbVie

(Free Report)

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Beh├žet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.

See Also

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBVFree Report).

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.